Martin Schneider

Company: Novartis

Job title: Associate Director

Seminars:

Modulating T cell Metabolism – From a Type I Kinase Inhibitor to an Oral Heterobifunctional Kinase Degrader 3:30 pm

Starting from an efficacious in vitro / in vivo active type I kinase inhibitor Degrading the kinase instead of blocking it has the same in vitro cellular effects on primary T cell metabolism Optimizing a kinase inhibitor into an oral bifunctional degrader for in vivo useRead more

day: Day Two